Common Challenges Impacting SEND Readiness
- eniivancesolutions
- Apr 6
- 2 min read
Introduction
With SEND now required for U.S. FDA submissions, its role extends beyond dataset creation and directly influences submission quality, review efficiency, and regulatory confidence.
However, achieving SEND readiness is often more complex than anticipated. What appears to be a structured, standards-driven process can become challenging in practice particularly across diverse studies, systems, and teams.
Understanding where organizations typically encounter difficulties can help improve overall submission readiness.
1. SEND Considerations Introduced Late in the Study Lifecycle
In many organizations, SEND-related activities begin close to submission timelines.
While this approach may seem efficient, it often results in:
Gaps in required data
Inconsistent terminology
Increased reliance on downstream corrections
These challenges can significantly impact timelines and increase the risk of rework.
2. Variability in Source Data Creates Hidden Complexity
Nonclinical data is typically generated across multiple systems, vendors, and study designs.
Variability in the following areas often introduces additional complexity when aligning with SEND expectations:
Data capture practices
Terminology usage
Study execution
This makes it more challenging to align data with SEND expectations and is a common source of inefficiencies during dataset preparation.
3. Limited Cross-Functional Alignment
SEND readiness depends on coordinated inputs from multiple functions, including toxicology, data management, statistical programming, and regulatory teams.
In practice, lack of alignment can lead to:
Differences in data interpretation
Delays in issue resolution
Inconsistent dataset structures
Achieving consistent cross-functional coordination remains a challenge for many organizations.
4. Manual Processes Do Not Scale Effectively
Reliance on manual mapping and validation workflows can create bottlenecks, particularly for organizations managing multiple or complex studies.
Common implications include:
Increased risk of errors
Longer turnaround times
Difficulty maintaining consistency across studies
As study volume grows, these limitations become more pronounced.
5. Validation Issues Identified Late in the Process
SEND validation is a critical component of submission readiness, especially in the context of regulatory expectations.
However, validation issues are often identified at later stages, leading to:
Iterative cycles of rework
Delays in submission timelines
Increased operational pressure
Late-stage issue detection can have a direct impact on submission quality.
6. Lack of a Clearly Defined SEND Operating Model
As organizations scale SEND activities, defining a clear operating model becomes increasingly important.
Without clarity on how SEND is managed whether in-house, outsourced, or hybrid, organizations may face:
Role ambiguity
Process inconsistencies
Challenges in scaling across studies
A structured and well-defined approach is essential to support consistent SEND readiness.
Conclusion
Achieving SEND readiness is not simply a technical exercise, it involves managing data variability, cross-functional dependencies, and regulatory expectations.
Organizations that recognize these challenges early are better positioned to:
Reduce rework
Improve consistency
Strengthen submission readiness
As SEND continues to play a central role in regulatory submissions, a more structured and experience-driven approach becomes increasingly important.
Comments